Table 1. Demographic and clinical characteristics of the studying cohort.
| Non-demented elders | MCI | CN | Aβ-positive participants | Aβ-negative participants | APOE ε 4 carriers | APOE ε 4 non-carriers | |
|---|---|---|---|---|---|---|---|
| n | 90 | 49 | 41 | 35 | 53 | 29 | 61 |
| Age (years) | 71.39 ± 6.45 | 70.60 ± 6.84 | 72.34 ± 6.00 | 73.03 ± 7.01 | 69.91 ± 5.48 b | 70.13 ± 6.89 | 71.99 ± 6.14 |
| Gender (Male/Female) | 34/56 | 33/16 | 23/18 | 14/21 | 20/33 | 10/19 | 24/37 |
| Education (years) | 16.39 ± 2.73 | 16.06 ± 3.14 | 16.78 ± 2.16 | 16.40 ± 2.75 | 16.40 ± 2.77 | 16.38 ± 3.02 | 16.39 ± 2.58 |
| Diagnosis (MCI/CN) | 49/41 | — | — | 22/13 | 26/27 | 18/11 | 31/30 |
| Genotype (GG/AG/AA) | 44/31/15 | 25/17/7 | 19/14/8 | 16/15/4 | 28/15/10 | 13/11/5 | 31/20/10 |
| APOE ε4 carriage (%) | 32.2 | 36.7 | 26.8 | 45.7 | 20.8 | — | — |
| Neuropsychological tests | |||||||
| MMSE | 28.36 ± 2.02 | 27.77 ± 2.32 | 29.05 ± 1.36 a | 27.91 ± 1.84 | 28.63 ± 2.10 b | 27.93 ± 2.18 | 28.57 ± 1.90 |
| CDR-SB | 0.81 ± 1.34 | 1.39 ± 1.57 | 0.09 ± 0.30 a | 1.21 ± 1.72 | 0.58 ± 0.97 | 1.05 ± 1.68 | 0.69 ± 1.11 |
| ADAS-cog11 | 7.19 ± 4.08 | 8.79 ± 4.53 | 5.32 ± 2.50 a | 8.09 ± 4.70 | 6.52 ± 3.39 | 7.34 ± 4.59 | 7.12 ± 3.81 |
| ADAS-cog13 | 11.36 ± 6.41 | 14.21 ± 6.87 | 8.10 ± 3.94 a | 12.66 ± 7.34 | 10.37 ± 5.62 | 11.79 ± 7.30 | 11.15 ± 6.03 |
Data are presented as mean ± SD; differences in characteristics between sub-groups were assessed using Chi-square test or Wilcoxon rank test.
Note: Two subjects lack of CSF and PET Aβ data were excluded in the analyses grouped by presence or absence of abnormal Aβ deposition.
Aβ = amyloid-beta; APOE = Apolipoprotein E; MCI = mild cognitive impairment; CN = control.
aMCI versus CN, p < 0.05.